Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Serrano

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
Breast Cancer Research and Treatment|August 4, 2016
A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifenHarriet Johansson, Sara Gandini, Davide Serrano, et al.
Tumori|January 20, 2025
<i>MLH1</i> promoter hypermethylation and Lynch Syndrome: When to test for constitutional epimutations of <i>MLH1</i> gene?Laura Cazzaniga, Cristina Zanzottera, Sara Mannucci, et al.
Contemporary Clinical Trials|August 20, 2010
Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodologyMatteo Lazzeroni, Aliana Guerrieri-Gonzaga, Davide Serrano, et al.
Breast Cancer Research and Treatment|November 19, 2013
Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinideHarriet Johansson, Bernardo Bonanni, Sara Gandini, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 16, 2015
Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical TrialAndrea DeCensi, Matteo Puntoni, Aliana Guerrieri-Gonzaga, et al.
The Pharmacogenomics Journal|April 11, 2019
Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancerHarriet Johansson, Valentina Aristarco, Sara Gandini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasiaBernardo Bonanni, Davide Serrano, Sara Gandini, et al.
International Journal of Cancer|July 7, 2016
Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCISAliana Guerrieri-Gonzaga, Ivana Sestak, Matteo Lazzeroni, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 2, 2016
A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer PatientsValentina Aristarco, Davide Serrano, Sara Gandini, et al.
Nutrients|October 23, 2021
The Association between Vitamin D and Gut Microbiota: A Systematic Review of Human StudiesFederica Bellerba, Valeria Muzio, Patrizia Gnagnarella, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Breast Cancer Research and Treatment|August 4, 2016
A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifenHarriet Johansson, Sara Gandini, Davide Serrano, et al.
Tumori|January 20, 2025
<i>MLH1</i> promoter hypermethylation and Lynch Syndrome: When to test for constitutional epimutations of <i>MLH1</i> gene?Laura Cazzaniga, Cristina Zanzottera, Sara Mannucci, et al.
Contemporary Clinical Trials|August 20, 2010
Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodologyMatteo Lazzeroni, Aliana Guerrieri-Gonzaga, Davide Serrano, et al.
Breast Cancer Research and Treatment|November 19, 2013
Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinideHarriet Johansson, Bernardo Bonanni, Sara Gandini, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 16, 2015
Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical TrialAndrea DeCensi, Matteo Puntoni, Aliana Guerrieri-Gonzaga, et al.
The Pharmacogenomics Journal|April 11, 2019
Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancerHarriet Johansson, Valentina Aristarco, Sara Gandini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasiaBernardo Bonanni, Davide Serrano, Sara Gandini, et al.
International Journal of Cancer|July 7, 2016
Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCISAliana Guerrieri-Gonzaga, Ivana Sestak, Matteo Lazzeroni, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 2, 2016
A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer PatientsValentina Aristarco, Davide Serrano, Sara Gandini, et al.
Nutrients|October 23, 2021
The Association between Vitamin D and Gut Microbiota: A Systematic Review of Human StudiesFederica Bellerba, Valeria Muzio, Patrizia Gnagnarella, et al.
Pageof 9